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Background: We previously conducted a phase I trial for advanced colorectal cancer (CRC) using five
HLA-A*2402-restricted peptides, three derived from oncoantigens and two from vascular endothelial growth
factor (VEGF) receptors, and confirmed safety and immunological responses. To evaluate clinical benefits of
cancer vaccination treatment, we conducted a phase II trial using the same peptides in combination with
oxaliplatin-based chemotherapy as a first-line therapy.
Methods: The primary objective of the study was the response rates (RR). Progression free survival (PFS), overall
survival (OS), and immunological parameters were evaluated as secondary objective. The planned sample size was
more than 40 patients for both HLA2402-matched and -unmatched groups. All patients received a cocktail of five
peptides (3 mg each) mixed with 1.5 ml of IFA which was subcutaneously administered weekly for the first 12 weeks
followed by biweekly administration. Presence or absence of the HLA-A*2402 genotype were used for classification of
patients into two groups.
Results: Between February 2009 and November 2012, ninety-six chemotherapy naïve CRC patients were enrolled
under the masking of their HLA-A status. Ninety-three patients received mFOLFOX6 and three received XELOX.
Bevacizumab was added in five patients. RR was 62.0% and 60.9% in the HLA-A*2402-matched and
-unmatched groups, respectively (p = 0.910). The median OS was 20.7 months in the HLA-A*2402-matched
group and 24.0 months in the unmatched group (log-rank, p = 0.489). In subgroup with a neutrophil/lymphocyte ratio
(NLR) of < 3.0, patients in the HLA-matched group did not survive significantly longer than those in the unmatched
group (log-rank, p = 0.289) but showed a delayed response.
Conclusions: Although no significance was observed for planned statistical efficacy endpoints, a delayed response was
observed in subgroup with a NLR of < 3.0. Biomarkers such as NLR might be useful for selecting patients with a better
treatment outcome by the vaccination.
Trial registration: Trial registration: UMIN000001791.
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Colorectal cancer (CRC) is the third most common can-
cer and the second leading cause of cancer-related death
in industrialized countries [1]. In the past decade, a com-
bination treatment of fluorinated-pyrimidine with irinote-
can (FOLFIRI) or oxaliplatin (FOLFOX, XELOX), with
or without monoclonal antibodies such as anti-vascular
endothelial growth factor (VEGF) antibody or anti-epidermal
growth factor receptor (EGFR) antibody, has markedly im-
proved the prognosis of patients with metastatic CRC
(mCRC) [2-6]. However, most of the patients reveal pro-
gression of the disease due to chemo-resistance and lose
their lives.
As an attempt to validate a new treatment modality to
overcome the limited disease control status of mCRC,
we conducted a combination treatment of five thera-
peutic epitope-peptides with chemotherapy. Recent de-
velopments in genome-based technologies have enabled
us to obtain comprehensive gene expression profiles of
malignant cells and compare them with normal cells [7].
We had previously identified three oncoantigens, RNF43
(ring finger protein 43) [8], 34 kDa translocase of the
outer mitochondrial membrane (TOMM34) [9], and
KOC1 (IMP-3; IGF-II mRNA binding protein 3) [10], as
targets for the development of cancer peptide vaccines
for CRC.
Although immunotherapy using tumor infiltrating cells
(TIL) or vaccine treatment are promising modalities for
the treatment of cancer, recent reports have indicated sev-
eral mechanisms in tumor tissues which make cancer cells
escape from immune system attacks [11]. For example,
the limited antitumor effects of cytotoxic T lymphocytes
(CTL) were explained by tumor heterogeneity; a subset of
tumor cells revealed the down-regulation or absence of
human leukocyte antigen (HLA) or targeted antigen
proteins [12,13]. Since the growth of solid neoplasms
is almost always accompanied with neovascularization
[14], which is associated with the expression of vascular
endothelial growth factor receptor 1 (VEGFR1) [15] and/or
VEGFR2 [16], our vaccine treatment also included the pep-
tides derived from VEGFR1 and VEGFR2 that target
neovascular endothelial cells. We selected five HLA-A*2402-
restricted peptides derived from RNF43, TOMM34, KOC1,
VEGFR1, and VEGFR2 for the clinical trial due to the
abundance of the HLA-A*2402 allele in the Japanese
population (an allelic frequency of approximately 60%)
[17]. We previously performed a phase Ι study of a com-
bination vaccine treatment for mCRC, and confirmed the
safety and the promising potential of our five-peptide-
cocktail treatment to improve the prognosis of advanced
CRC [18].
FOLFOX (or XELOX) with/without bevacizumab is a
widely-used chemotherapy [4] and has been reported to
possibly reduce the number of Tregs [19]. We thereforeconducted a phase II study of a cancer vaccine consisting
of five peptides in combination with oxaliplatin-based
chemotherapy as a first-line therapy for advanced CRC.
The purpose of this study was to evaluate the clinical
benefit of this cancer vaccine treatment by adding to
oxaliplatin-based chemotherapy. Furthermore, we ex-
plored a predictive biomarker for its response and for
the selection of patients who are likely to exhibit better
treatment outcomes following the vaccine treatment.
We here demonstrate a promising result of our combin-
ation immuno-chemotherapy and predictive biomarkers
for immunotherapy.
Patients and methods
Patients and eligibility criteria
Patients were eligible for enrollment when they were ≥
20 years old with a histologically confirmed advanced
CRC, had one or more measurable lesions according to
the Response Evaluation Criteria in Solid Tumors version
1.0 (RECIST), were naïve for chemotherapy, had ad-
equate functions of critical organs, had an ECOG per-
formance status (PS) of 0 or 1, and had a life expectancy
of ≥ 3 months. The exclusion criteria were CNS involve-
ment, second primary tumors, active infectious disease,
any steroid treatment, or any prior peptide vaccination
therapies. Written informed consent was obtained from
each patient at the time of enrollment. The study was car-
ried out in accordance with the Helsinki declaration on
experimentation on human subjects, was approved by the
Institutional Ethics Review Boards of Yamaguchi University
(H20-102) and each study site, and was registered in the
UMIN Clinical Trials Registry as UMIN000001791.
Peptides
The RNF43-721 (NSQPVWLCL) [20], TOMM34-299
(KLRQEVKQNL) [9], KOC1(IMP-3)-508 (KTVNELQNL)
[21], VEGFR1-1084 (SYGVLLWEI) [22] and VEGFR2-169
(RFVPDGNRI) [23] peptides restricted with HLA-A*2402
were synthesized by American Peptide Company Inc.
(Sunnyvale, CA, USA) according to a standard solid-phase
synthesis method, and were purified by reverse-phase high
performance liquid chromatography (HPLC). The purity
(> 95%) and the identity of the peptides were determined
by analytical HPLC and mass spectrometry analysis, re-
spectively. Endotoxin levels and the bio-burden of these
peptides were tested and determined to be within accept-
able levels as Good Manufacturing Practice grade for
vaccines.
Study design
This phase II, single arm, non-randomized, HLA-A status
double-blind study was conducted to assess the efficacy of
this combination therapy for first-line treatment for ad-
vanced CRC. The therapy consisted of a cocktail of five
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containing chemotherapy. Although the peptides used in
this study were HLA-A*2402 restricted peptides, all en-
rolled patients whose HLA-A status were double-blinded
were administrated the same regime of peptide cocktail
and oxaliplatin-containing chemotherapy.
The cocktail of 3 mg each of five peptides derived from
RNF43-721, TOMM34-299, KOC1-508, VEGFR1-1084
and VEGFR2-169, was mixed with 1.5 ml of incomplete
Freund’s adjuvant (IFA) (Montanide ISA51; Seppic, Paris,
France) and administered subcutaneously into the thigh
or axilla regions on day 1 of each week for 13 weeks, then
the vaccination schedule was reduced to once every 2 weeks.
Vaccination was continued even if the disease progressed
when the patient wished and a primary doctor who pro-
vided additional chemotherapies agreed.
Oxaliplatin-containing regimens were administrated
concurrently with the vaccination. Detailed informations
of the chemotherapies were described in Additional file
1. Briefly, mFOLFOX6 [24,25] consisted of oxaliplatin
(85 mg/m2) with leucovorin (400 mg/m2), followed by a
FU (400 mg/m2) bolus, and then 2,400 mg/m2 continu-
ous infusion with/without bevacizumab (5 mg/kg) [4].
This treatment was repeated every 14 days. XELOX [4]
consisted of oxaliplatin (130 mg/m2) on day 1 followed
by oral capecitabine (1,000 mg/m2) twice daily on days 1
through 14 of a 21-day cycle with/without bevacizumab
at a dose of 7.5 mg/kg.
Study objectives
The primary objective was the comparison of the efficacy
of the peptide-cocktail plus oxaliplatin-containing regimen
on patients with HLA-A*2402 compared with those with-
out HLA-A*2402 by assessing the objective response rate
(ORR; complete response (CR) and partial response (PR)).Figure 1 CONSORT diagram. Scheme showing an HLA-A-status doubl
epitope-peptides combined with oxaliplatin-based chemotherapy as a f
colorectal cancer; FOLFOX, infusional fluorouracil, leucovorin, and oxalip
leukocyte antigen.Secondary objectives included comparisons between the
two groups for progression free survival (PFS), overall sur-
vival (OS), safety, and tolerability. Exploratory end points
included the assessments of tumor and blood-based im-
munological biomarkers.
Assessments
Medical history, physical examination, chest X-ray, ECG,
and carcinoembryonic antigen (CEA) measurements were
performed within 21 days before starting the treatment.
Assessments of vital signs, ECOG performance status,
height, weight, and routine blood analysis (hematology
and chemistry) were performed within 7 days of starting
the treatment. During treatment, physical examination,
hematology, and biochemistry analyses were repeated on
day 1 of every treatment cycle. Tumor assessments (com-
puted tomography scan, magnetic resonance imaging)
were made before starting the study treatment and were
repeated every 4 to 8 weeks after the treatment. The
RECIST guidelines were used to define all responses. Signs
of hematological toxicity and non-hematological toxicity
were assessed according to CTCAE during therapy and
for 28 days after the last study drug dose.
Immunological biomarkers
We investigated the neutrophil/lymphocyte ratio (NLR)
and the peripheral blood lymphocyte counts per the entire
white blood cells (lymphocyte-%) before the treatment as
predictive markers of the efficacy of the vaccination. NLR
and lymphocyte-% were determined immediately at each
study site.
Statistical analysis
This study was designed to test the hypothesis that a re-
gime consisting of vaccination plus oxaliplatin-containinge-blind, biologically-randomized phase ΙI study of five therapeutic
irst-line therapy for advanced colorectal cancer (FXV study). CRC,
latin; XELOX, capecitabine and oxaliplatin; HLA, human








Male 25 24 NS
Female 25 22
Age
Mean 64.3 63.4 NS













Resection of primary lesion
yes 41 43
no 9 3 NS
Chemotherapy
FOLFOX 48 45
XELOX 2 1 NS
(Bevacizumab) 0 (5)
Primary minor site
Colon 29 36 0.057
Rectal 21 10
FOLFOX. infusional fluorouracil. leucovorin. and oxaliplatin: XELOX. capecitabine
and oxaliplatin; HLA, human leukocyte antigen; NS. not significant.
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A*2402 positive aCRC when compared to those without
HLA-A*2402, defining the HLA-A*2402 matched group
as the study group and the unmatched group as the con-
trol group. Because the response rate of colorectal cancer
patients to first line-treatment is generally about 50%, we
estimated that a minimum of 40 patients for both arms
would be required, assuming a response rate of 50% in theTable 2 Objective Response rate
HLA-status HLA-A*2402-matched (n =
Response CR PR SD P
Number 1 30 16 3
Response rate 31/50 (62.0%)HLA-unmatched control group and 65% in the HLA-
matched study group. A two-sided Alpha level of 0.2 and
a beta level of 0.5 were assumed.
Response rates were compared by chi-squared test. OS
and PFS rates were analyzed by the Kaplan-Meier method
and log rank test. For the evaluation of delayed response,
we also performed a supplemental analysis of the weighted
log-rank tests with the Harrington-Fleming class of weights
test for 3 parameter settings (ρ = 0 and γ = 0.5; ρ = 0
and γ = 1; ρ = 0 and γ = 2) [26].
Statistical analyses were performed using SPSS statis-
tics version 20 (SPSS, Chicago, IL, USA) and SAS v9.2.
A p value < 0.05 was considered statistically significant.
Results
Patients
Between January 2009 and November 2012, ninety-six
patients were enrolled in this trial applying the peptide
cocktail treatment in combination with an oxaliplatin-
based regimen in 13 hospitals. Fifty patients had at least
one allele of HLA-A*2402 and forty-six patients had no
HLA-A*2402 allele. The peptide vaccination was admin-
istered to all patients. Among the 96 patients enrolled to
this trial, 93 patients received mFOLFOX6 and three
received XELOX. Five patients were additionally treated
with bevacizumab (Figure 1). The baseline characteristics
were generally well balanced between the HLA-matched
and HLA-unmatched groups, although the proportion of
rectal cancer was slightly higher in the HLA-matched
group (Table 1). On the cut-off date (25 December, 2013),
87 patients (91%) revealed the progression of the disease
with the median OS follow-up period of 38.2 months.
Objective response rate
The ORR was 62.0% and 60.9% in the HLA-matched and
HLA-unmatched groups (p = 0.910), respectively (Table 2).
The proportions of CR, PR, and SD as well as the disease
control rate were 2.0% (1/50), 60.0% (30/50), 32.0% (16/50),
and 94.0% (47/50) in the HLA-matched group, respectively,
and 0% (0/46), 60.9% (28/46), 37.0% (17/46), 97.8% (45/46)
in the HLA-unmatched group, respectively.
Progression free survival
The median PFS was 7.2 months for the HLA-matched
group and 8.7 months for the HLA-unmatched group. There
was no significant difference between two groups (Figure 2A,
P = 0.971). We also performed sub-group analyses using50) HLA-A*2402-unmatched (n = 46)
D CR PR SD PD
0 28 17 1
28/46 (60.9%)
Figure 2 Progression free survival and overall survival. A and B, comparison of progression free survival between HLA-A*2402-mached
and -unmatched groups; A, all patients; B, the patients who received the vaccination for more than 12 months. C and D, comparison of overall
survival between HLA-A*2402-matched and -unmatched groups; C, all patients; D, patients who received the vaccination for more than 12 months.
MST, median survival time; HLA, human leukocyte antigen; M, months; *the weighted log-rank tests with the Harrington-Fleming class of weights
were performed and resulted in, ρ = 0, and γ = 0.5, p = 0.186; ρ = 0, and γ = 1, ρ = 0.080; ρ = 0, and γ = 2, ρ = 0.101.
Hazama et al. Journal of Translational Medicine 2014, 12:108 Page 5 of 10
http://www.translational-medicine.com/content/12/1/108the patients who received the vaccination for more than
12 months, but there was also no difference between these
two groups (Figure 2B, P = 0.946).
Overall survival
The median OS was calculated to be 20.7 months in the
HLA-A*2402-matched group and 24.0 months in the
unmatched group. There was no significant difference
between the two groups (Figure 2C; log-rank test, p =
0.489; Harrington-Fleming method, ρ = 0 and γ = 0.5,
p = 0.186; ρ = 0 and γ = 1, p = 0.080; ρ = 0 and γ = 2, p =
0.101). Interestingly, when the patients were able to re-
ceive the vaccination for more than 12 months, the OS of
the HLA-A*2402-matched group was significantly better
than that of the unmatched group (Figure 2D; log-rank
test, p = 0.032).
Safety
The most common adverse events (AEs) observed in this
trial were neurologic toxicity and hematologic toxicities
(Table 3). There was no significant difference in the inci-
dence of AEs including injection site reaction in the two
groups. Although the incidences of serious adverse events(SAEs) were almost similar in the two groups, that of neu-
tropenia was relatively higher in the HLA-A*2402-matched
group than the unmatched group. Interstitial pneumo-
nia that led to the death was observed in two cases
in the HLA-matched group and in one case in the HLA-
unmatched group (Table 4).
Immunological biomarkers
NLR is defined as the neutrophil to lymphocyte ratio,
and in this study we categorized the patients into two
groups (< 3 and ≧ 3) according to the papers reported
previously [27]. In this study, NLR of <3.0 was a prog-
nostic marker for the longer survival with peptide cock-
tail and oxaliplatin-containing chemotherapy (Figure 3A;
log-rank test, p = 0.043). The Lymphocyte-% of ≧ 15%
was also associated with a long survival (Figure 3B; log-
rank test, p = 0.034). Hence, we examined the combined
effect of each of these two markers and the HLA types
on the clinical efficacy of the vaccination. In patients
with a NLR of < 3.0, a significantly longer overall survival
was observed in the HLA-A*2402-matched group than
the HLA-A*2402-unmatched group (Figure 3C; log-rank
test, P = 0.289; Harrington-Fleming method, ρ = 0 and γ =
Table 3 Frequent and Severe Adverse Events (CTCAE version 3.0)
FOLFOX (n = 89), FOLFOX + Bev (n = 4), XELOX + Bev (n = 1)
HLA-A*2402-matched (n = 50) HLA-A*2402-unmatched (n = 46)
FOLFOX (n = 48), XELOX (n = 2) FOLFOX (n = 41) + Bev (n = 4), XELOX + Bev (n = 1)
Adverse Event
1 2 3 4 5 1 2 3 4 5
No % No % No % No % No % No % No % No % No % No %
Hand-foot syndrome 0 0 0 0 1 2 0 0 0 0 1 2 0 0 1 2 0 0 0 0
Allergy 4 8 3 6 2 4 0 0 0 0 3 7 4 9 0 0 0 0 0 0
Mucositis 2 4 1 2 1 2 0 0 0 0 2 4 0 0 0 0 0 0 0 0
Nausea/vomiting 5 10 1 2 2 4 0 0 0 0 6 13 2 4 1 2 0 0 0 0
Neurologic toxicity 15 30 10 20 4 8 0 0 0 17 37 10 22 5 11 1 2 0 0
Anorexia 10 20 3 6 4 8 0 0 0 0 10 22 4 9 2 4 0 0 0 0
Diarrhea 3 6 6 12 2 4 0 0 0 0 3 7 0 0 1 2 0 0 0 0
Fatigue/Asthenia 5 10 1 2 2 4 0 0 0 0 5 11 1 2 1 2 0 0 0 0
Fever 2 4 0 0 0 0 0 0 0 0 3 7 2 4 0 0 0 0 0 0
Injection site reaction 18 36 18 36 9 18 0 0 0 0 20 43 17 37 3 13 0 0 0 0
Interstitial pneumonia 0 0 0 0 4 8 0 0 2 4 0 0 0 0 4 9 0 0 1 2
Neutropenia 5 10 10 20 10 20 1 2 0 0 8 17 14 30 2 4 1 2 0 0
Leukopenia 10 20 12 24 1 2 0 0 0 0 12 26 9 20 2 4 0 0 0 0
Thrombocytopenia 17 34 3 6 0 0 0 0 0 0 20 43 2 4 0 0 0 0 0 0
Bilirubin 2 4 2 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
AL-P 11 22 1 2 1 2 0 0 0 0 10 22 1 2 0 0 0 0 0 0
Creatinine 3 6 1 2 0 0 0 0 0 0 1 2 0 0 0 0 0 0 0 0
Hemoglobin 11 22 5 10 0 0 0 0 0 0 13 28 7 15 0 0 0 0 0 0
Embolism 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 2 0 0
AST/ALT 12 24 0 0 1 2 0 0 0 0 6 13 1 2 0 0 0 0 0 0
No gastrointestinal perforation nor bleeding wound healing complication was observed. FOLFOX, infusional fluorouracil, leucovorin, and oxaliplatin; XELOX,
capecitabine and oxaliplatin; Bev, bevacizumab; AL-P, alkaline phosphatese; AST, aspartete aminotransfarase; ALT, alanine aminotransferase; CTCAE, the Common
Terminology Criteria for Adverse Event version 3.0; HLA, Human leukocyte antigen.
Table 4 Interstitial Pneumonia











3004/3303 5 not examined
1101/3101 3 not examined
CTCAE, the Common Terminology Criteria for Adverse Event version 3.0; HLA,
Human leukocyte antigen; DLTT, drug-induced lymphocyte transformation test;
5FU, 5-fluorouracil.
Hazama et al. Journal of Translational Medicine 2014, 12:108 Page 6 of 10
http://www.translational-medicine.com/content/12/1/1080.5, p = 0.152; ρ = 0 and γ = 1, p = 0.064; ρ = 0 and γ = 2,
p = 0.035) while this difference was not observed in
patients with NLR of ≧ 3.0 (log-lank test, p = 0.962;
Harrington-Fleming method, ρ = 0 and γ = 0.5, p = 0.495;
ρ = 0 and γ = 1, p = 0.346; ρ = 0 and γ = 2, p = 0.251). Simi-
larly, in a patient group with a lymphocyte% of > 15%, a
longer overall survival was observed in the HLA-A*2402-
matched group (Figure 3D; log-lank test, p = 0.340;
Harrington-Fleming method, ρ = 0 and γ = 0.5, p = 0.114;
ρ = 0 and γ = 1, p = 0.051; ρ = 0 and γ = 2, p = 0.029).
Discussion
We performed a phase II study using a cocktail of five epi-
tope peptides, which we previously confirmed its safety,
together with oxaliplatin-based chemotherapy. The cock-
tail contained three peptides derived from three oncoanti-
gens and two peptides targeting VEGFR1 and VEGFR2.
This study was an HLA-A-status double-blind, phase ΙI
study of five therapeutic epitope-peptides with oxaliplatin-
based chemotherapy as a first-line therapy for advanced
Figure 3 Biomarkers for the survival and the clinical efficacy of vaccination. Neutrophil/lymphocyte ratio (NLR) < 3.0 and Lymphocyte-% ≧
15% were considered as indicative factors. A and B, comparison between the favorite group and others. C, comparison of the patients with a
NLR of ≧ 3 or a NLR of <3 between the HLA-A*2402-matched and -unmatched groups. D, comparison of the patients with Lymphocyte-% ≧ 15%
between the HLA-A*2402 positive and negative groups. Lymphocyte (Ly)-%, the percentage of lymphocytes among the peripheral leukocytes;
NLR, neutrophil/lymphocyte ratio; HLA, human leukocyte antigen; L-R, log-rank test; *the weighted log-rank tests with the Harrington-Fleming
class of weights were performed and resulted in, ρ = 0, and γ = 0.5, p = 0.152; ρ = 0, and γ = 1, p = 0.064; ρ = 0, and γ = 2, p = 0.035; **the
Harrington-Fleming tests were resulted in, ρ = 0, and γ = 0.5, p = 0.495; ρ = 0, and γ = 1, ρ = 0.346; ρ = 0, and γ = 2, ρ = 0.251; *** the
Harrington-Fleming tests were resulted in, ρ = 0, and γ = 0.5, p = 0.114; ρ = 0, and γ = 1, ρ = 0.051; ρ = 0, and γ = 2, ρ = 0.029.
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many interesting results.
Firstly, the OS of the HLA-A*2402-matched group was
significantly higher compared to that of the unmatched
group (log-rank test, p = 0.032) when patients who received
the vaccination for more than 12 months (Figure 2D) al-
though no difference in PFS was observed between the
two groups (Figures 2B). These results indicated that
the additional effect of vaccination on the standard
chemotherapy was likely to be slow-acting as this kind of
delayed response by the vaccine treatment was indicated
in the guidance for therapeutic cancer vaccines released
from the US Food and Drug Administration in October,
2011 [28].
Secondly, neutrophil/lymphocyte ratio (NLR) might be-
come a prognostic marker for patients who received the
peptide vaccine in combination with standard chemo-
therapy (Figure 3A, log-rank; p = 0.043), and there was anobvious tail effect for extremely long survival. Then we
examined the efficacy of vaccination by comparing HLA-
matched group and -unmatched group. In patients with
an NLR of < 3.0, a significantly longer survival in the
HLA-matched group than the HLA-unmatched group
was observed (Figure 3B; log-rank, p = 0.289; Harrington-
Fleming, p = 0.035), while this difference was not observed
in the two groups with NLR of ≧ 3.0 (log-rank, p = 0.962;
Harrington-Fleming, p = 0.251). This result also support
the idea that it may be critically important to apply
vaccine treatment to patients with better immune sta-
tus, and NLR might be a one of good predictive markers
to select the appropriate patient populations for this
type of treatment. A similar result was observed when
we analyzed patients with lymphocyte% of ≧ 15%;
HLA-matched patients with lymphocyte% of ≧ 15 showed
significantly better prognosis than HLA-unmatched pa-
tients (Figure 3D; log-rank, p = 0.340; Harrington-Fleming,
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and higher lymphocyte percentage might be useful to the
selection of patients who are likely to respond well to
vaccine treatment and improve clinical outcomes.
Vaccinations with a cocktail of five peptides together
with oxaliplatin-based chemotherapy in metastatic CRC
patients were well tolerated, except for relatively frequent
cases (11 cases; 11.4%) of pneumonitis (Tables 3 and 4),
whose incidence seemed to be higher than previously
reported for oxaliplatin-based chemotherapies although
no difference was observed between HLA-matched
and -unmatched group. Correale et al. reported two
cases (5.5%) in 36 patients with advanced gastric cancer
treated with gemcitabine plus oxaliplatin, folinic acid, and
5-fluorouracil (FOLFOX-4) [29]. Usui et al. reported that
four cases (3.9%) of pneumonitis among 104 Japanese
patients treated with oxaliplatin-containing regimes for
advanced colorectal cancer [30]. In addition, there have
been many case reports of oxaliplatin-related pneumonitis
[31-35]. In this study, eleven (11.4%) of 96 patients suf-
fered from severe pneumonitis including three cases with
grade 5 pneumonitis. To investigate the possible cause of
pneumonitiswe performed drug-induced lymphocyte trans-
formation test (DLTT) for nine patients whose samples
were available. Among them, five patients (55.6%) were
judged to be positive to fluorouracil alone, and the remaining
four patients were negative for all of the antigens tested.
Although the size of this study is not large enough to
make any conclusion and there is no difference between
the two groups, this adverse event should be carefully
monitored when we will perform the next-step clinical
trial.
Although the efficacy of our peptide vaccine was not
clearly demonstrated in this phase II study, the timing of
and combination treatment with vaccination might not
be optimized, and the sample size was limited. Recently,
regulatory T cells (Tregs) and myeloid-derived suppres-
sor cells (MDSCs) are reported as potent immunosuppres-
sive cells to protect cancer cells from the host immune
system [36,37]. Over expression of PD-L1and PD-1 as well
as up-regulation of indoleamine-2,3-dioxygenase (IDO) in
the tumor microenvironment also inhibit the CTL func-
tions [38]. Hence, to overcome these immune-escape
mechanisms, various approaches have been taken in the
last decade [39,40]. For example, anti-PD1antibody [41],
anti-PD-L1antibody [42], and anti-CTL4 antibody [43]
were applied in clinical trials to overcome the suppressive
immuno checkpoints, and surprisingly high objective
response rates were observed in many types of malignant
neoplasm. Small-molecule inhibitors [44] that block IDO
enzymatic activity or cyclophosphamide to reduce the
number of Tregs [45] were also applied in clinical trials to
dissolve the suppressive immunity. For the successful
next generation immunotherapy, peptide vaccine shouldbe combined with some agents to modify the immune-
suppressive tumor microenvironments.
In conclusion, our cocktail of five therapeutic epitope
peptides appears to be effective in a subset of patients,
and warrants a randomized phase III study. In the phase
III study, biomarkers such as NLR and lymphocyte-%
might be useful for assessing the response to the peptide
vaccine and for selecting patients likely to have a better
treatment outcome with the vaccination.
Conclusions
This phase II cancer vaccine therapy demonstrated that
our therapeutic peptides cocktail was likely to be effect-
ive in a subset of patients and warrants a randomized
phase III study. In the phase III study, predictive bio-
markers such as NLR and lymphocyte-% should be used
for its response and for selecting patients to have a bet-
ter treatment outcome with the vaccination.
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